Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more

Location: 116 Huntington Avenue, Boston, MA, 02116, United States | Website: https://www.bicara.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.027B

52 Wk Range

$7.80 - $28.09

Previous Close

$18.81

Open

$18.97

Volume

800,812

Day Range

$18.44 - $19.24

Enterprise Value

477.4M

Cash

436.6M

Avg Qtr Burn

-25.24M

Insider Ownership

12.20%

Institutional Own.

93.99%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.